Adashek, Jacob J. http://orcid.org/0000-0003-4272-312X
LoRusso, Patricia M.
Hong, David S.
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Article History
Accepted: 1 August 2019
First Online: 2 September 2019
Competing interests
: P.M.L. is an advisory board member for Agenus, Cyrexa, CytomX and Genentech; a data safety monitoring board or committee member for Agios, FivePrime and Halozyme; an imCORE Alliance member for Roche; and a consultant for SOTIO. D.S.H. receives research and/or grant support from AbbVie, Adaptimmune, Amgen, Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, MiRNA, Molecular Templates, Mologen, NCI–CTEP, Novartis, Pfizer, Seattle Genetics and Takeda; travel and accommodation support from AACR, ASCO, Genmab, LOXO, MiRNA and SITC; is a consultant or adviser for Alpha Insights, Axiom, Adaptimmune, Baxter, Bayer, Genentech, GLG, Group H, Guidepoint Global, Infinity, Janssen, Merrimack, Medscape, Molecular Match, Numab, Presagia, Pfizer, Seattle Genetics, Takeda, Trieza Therapeutics and WebMD; and is a founder of OncoResponse. R.K. owns stock and has other equity interests in CureMatch, IDbyDNA and Soluventis; is a consultant or adviser for Actuate Therapeutic, Gaido, LOXO, NeoMed, Roche, Soluventis and X-Biotech; has received speaker’s fees from Roche; is a board member of CureMatch; and her institution receives research support from Foundation Medicine, Genentech, Grifols, Guardant Health, Incyte, Konica Minolta Merck Serono, OmniSeq, Pfizer and Sequenom. J.J.A. declares no competing interests.